Spotlight Asset Group’s Fortress Biotech FBIO Stock Holding History

Spotlight Asset Group’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-713	Closed	-$7K	–	251
2023 Q1	$7K	Buy	+713	New	+$8.49K	0.01%	76
2022 Q3	$7K	Buy	+713	New	+$10.7K	0.01%	76
2021 Q3	$34K	Hold	713	–	–	0.02%	116
2021 Q2	$38K	Hold	713	–	–	0.01%	129
2021 Q1	$38K	Buy	+713	New	+$40.2K	0.01%	131

Other funds holding FBIO

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Corient Private Wealth Miami, Florida $72.2B AUM 27.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1WM

1900 Wealth Management San Antonio, Texas $1.84B AUM 13.16% 1-Year Est. Return

Spotlight Asset Group's FBIO Position: Q2 2023 in Review

Spotlight Asset Group sold out of Fortress Biotech (FBIO) in Q2 2023, closing a stake of 713 shares — an estimated $7K sold.

Spotlight Asset Group first reported a position in FBIO in Q1 2021 and held it in 5 quarters. The position peaked at $38K in Q2 2021. 48 funds tracked by Wall St. Rank hold FBIO as of Q2 2023.

Spotlight Asset Group reported no remaining Fortress Biotech position as of Q2 2023 after selling out during the quarter.
Spotlight Asset Group sold 713 Fortress Biotech shares in Q2 2023, an estimated $7K.
Spotlight Asset Group first reported a position in Fortress Biotech in Q1 2021 and held it in 5 quarters.
Spotlight Asset Group's Fortress Biotech position peaked at $38K in Q2 2021.
48 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2023.

Based on Spotlight Asset Group's 13F filing for Q2 2023, filed 9 Aug 2023.